Moleculin Biotech released its H.C. Wainwright 28th Annual Global Investment Conference presentation on September 11, 2026. The update features interim Phase 3 data for Annamycin, its lead drug candidate for relapsed or refractory acute myeloid leukemia (AML).
Interim data shows Annamycin achieved higher complete remission rates than the control arm. The drug candidate demonstrated no detectable cardiotoxicity, a significant improvement over current standard-of-care anthracyclines.
The MIRACLE Phase 3 trial is currently ongoing. Management expects to complete enrollment for Part A in the third quarter of 2026. A second unblinded data readout is anticipated for late 2026 or early 2027.
Company management will also attend the conference for investor meetings from September 14-16.